

Ref: EPL/CS/SE/0054/2026

Date: July 03, 2026

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai - 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Acquisition/ investment in step-down subsidiary by subsidiary

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations") and in furtherance to the disclosure made in the Prospectus filed with the Securities Exchange Board of India, during the Initial Public Offer of the Company, we wish to inform you that Marcan Pharmaceuticals Inc., a subsidiary of the Company ("Marcan") has on July 02, 2026 (EDT) entered into share purchase agreements with certain shareholders of Mantra Pharma Inc., a step-down subsidiary of the Company ("Mantra"), to acquire all of Class E Special Shares in the share capital of Mantra. Consequently, Mantra continues to be 100% subsidiary of Marcan.

The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the LODR Regulations are provided in **Annexure A**, enclosed herewith.

The intimation is being made within reasonable time upon occurrence of the event, taking into account the applicable time-zone difference.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

Amruta Yangelwar
Company Secretary and Compliance Officer
Membership No.: A25687

Encl: As above

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 - 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251

Annexure A

Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr. No	Particulars	Information
a)	Name of the target entity, details in brief such as size, turnover etc.	<p>Mantra Pharma Inc., a company incorporated under the laws of Quebec, Canada (“Mantra”). Mantra is engaged in the marketing and distribution of prescription drugs and natural health products.</p> <p>Annual Turnover: CAD \$ 96.67 million</p> <p>Market: Canada</p> <p>Capital Structure: The issued, subscribed and paid up share capital is 1,000 Class A Common Shares and 24,000,000 Class E Special Shares without par value.</p>
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	<p>The acquisition (by subsidiary into step-down subsidiary) constitutes a related party transaction between two wholly-owned subsidiaries, exempted under Regulation 23(5) of LODR Regulations. The transaction shall be undertaken at arm’s length basis.</p> <p>Except as step-down subsidiary of the Company, the promoter / promoter group/ group companies of the Company do not have any interest in Mantra.</p>
c)	Industry to which the entity being acquired belongs	Pharmaceuticals
d)	Objects and impacts of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	In accordance with the terms of the Preferred Share Purchase Agreements entered into during the acquisition of Mantra as described in point ‘j’ below, Marcan is purchasing all of the Preferred shares i.e., Class E Special Shares from certain shareholders of Mantra.

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251

Emcure

e)	Brief details of any governmental or regulatory approvals required for the acquisition	The acquisition is subject to completion of requisite compliances in accordance with applicable laws in Canada. No specific government approvals are required.
f)	Indicative time period for completion of the acquisition	On July 03, 2026
g)	Nature of consideration - whether cash consideration or share swap and details of the same	Cash Consideration
h)	Cost of acquisition or the price at which the shares are acquired	An aggregate consideration of CAD \$ 50 million.
i)	Percentage of shareholding/control acquired and/ or number of shares acquired	100% of Class E Special Shares
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Mantra, a wholly owned subsidiary of Marcan Pharmaceuticals Inc. ("Marcan") was formed on November 06, 2023 under the Business Corporation Act (Quebec) by amalgamation between 9501-2969 Québec Inc. (a company incorporated and capitalized by Marcan on October 16, 2023), Mantra Pharma Inc. (erstwhile Mantra), Myriad Pharma Inc., Mantra Distribution Inc., Holding JFL Inc., Gestion Nirdac Inc., Gestion Stéphane Turcotte Inc., Gestion Beflan Inc. and Gestion Éléoraph Inc.</p> <p>The company operates primarily in the Canadian market. The aggregate historical turnover for the last three financial years is approximately:</p> <p>Financial Year 2026: CAD \$ 96.67 million Financial Year 2025: CAD \$ 81.01 million Financial Year 2024: CAD \$ 28.26 million*</p> <p><i>*For the period November 06, 2023 till March 31, 2024.</i></p>

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251